Navigation Links
Food and Drug Law Institute Sponsors Major Enforcement Conference
Date:12/20/2007

Top FDA and DOJ Officials, Legal Experts to Discuss Latest Criminal Cases, Decrees and How They Now Apply to Food and Dietary Supplement Industries

WASHINGTON, Dec. 20 /PRNewswire-USNewswire/ -- In the last year, mainstream drug and device companies have agreed to pay more than $1.9 billion in fines, civil settlements and penalties. Top drug company executives have paid multimillion dollar fines even though they did not participate in or know about the crimes.

With the Federal Government increasingly seeking legal action against pharmaceutical and device companies -- even those who didn't intend to do anything wrong -- there's a burgeoning need for food and drug industry stakeholder to stay current with federal enforcement developments.

To help meet those needs, the Food and Drug Law Institute is sponsoring its 6th Annual Conference on Enforcement & Litigation: Consent Decrees, Criminal Cases and Corporate Integrity Agreements, Feb. 19-20 at the L'Enfant Plaza Hotel in Washington, D.C.

At the conference, experts will discuss the latest enforcement actions and litigation and ways that voluntary implementation measures required by corporate integrity agreements and consent decrees can help food, drug and device firms stay clear of expensive and often demoralizing action.

Conferees will hear directly from Food and Drug Administration and Department of Justice officials, including luncheon speaker Gerald R. Masoudi, FDA's Chief Counsel and Eugene Thirolf, Director of DOJ's Office of Consumer Litigation. Other FDA officials include Deborah Autor, Director of Compliance, CDER; Joseph R. Baca, Director of Food Safety, CFSAN; Eric M. Blumberg, Deputy Chief Counsel for Litigation; Garry L. Coody, National Health Fraud Coordinator, Office of Enforcement, ORA; David K. Elder, Director, Office of Enforcement, Office of Regulatory Affairs; Annamarie Kempic, Associate Deputy for Litigation; Mary Anne Malarkey, Director, Office of Compliance & Biologics Quality, CBER; Vernessa T. Pollard, Associate Chief Counsel - Enforcement, OCC; Michael C. Rogers, Director, Office of Field Investigations, Office of Regulatory Affairs; Steven D. Silverman, Assistant Director, Officer of Compliance, CDER; Laura M. Tarentino, Office of Food Additive Safety, CFSAN; and Timothy A. Ulatowski, Director of Compliance, CDRH.

To register for the conference, visit http://www.fdli.org or call (800) 956-6923 or (202) 371-1420.

Founded in 1949, FDLI publishes the award-winning, peer-reviewed Food and Drug Law Journal; the bimonthly magazine Update; FDA Directory; and dozens of books and publications for attorneys, regulatory affairs practitioners, scientists, health care professionals, government employees and marketers in the food and drug field. For more information, visit http://www.fdli.org


'/>"/>
SOURCE Food and Drug Law Institute
Copyright©2007 PR Newswire.
All rights reserved

Related medicine news :

1. The Risk Management and Patient Safety Institute Announces Annual Health Care Risk Conference Dates
2. Mayo Clinic Multidisciplinary Simulation Center Receives Distinction as an ACS-Accredited Education Institute
3. LifeNet Health Establishes The Skin & Wound Allograft Institute
4. Statement from Employment Policies Institute on Senator Hillary Clintons Health Care Plan
5. CAS Medical Systems, Inc. Awarded $2.8 Million Grant by National Institutes of Health
6. Portico Systems to Share Provider Network Management Best Practices at Institute for International Research
7. The Integrated Benefits Institute Offers Largest Benchmarking Database in U.S. Spanning Disability and Workers Compensation Programs
8. The Cooper Institutes FITNESSGRAM Selected as Statewide Physical Fitness Assessment Tool
9. Bullying Prevention Institute Designed to Empower Change in Schools
10. Southern Research Institutes Neurodegenerative Disease Drug Discovery Program Receives National Institute of Mental Health Funding
11. Corey McPherson Nash Develops Case Statement for Dana-Farber Cancer Institute Capital Campaign
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/25/2017)... ... June 25, 2017 , ... CareSet Labs released the Root ... Orleans. This is a new, greatly improved version of the Doctor Referral teaming dataset ... by Fred Trotter and subsequently called the the “Doctor Referral Dataset” as released by ...
(Date:6/24/2017)... ... June 24, 2017 , ... Dr. Mitchell Mehlman and his ... Lake Ronkonkoma, Dental365 offers patients high-quality and affordable routine and emergency dental care. ... fit into their patients’ busy lifestyles. Dental365 also gladly work with most insurance ...
(Date:6/23/2017)... ... 2017 , ... By scoring 100% for fiscal management and accountability, the Arthritis ... charity evaluator, Charity Navigator, validating ANRF's work as a top charity in America. , ... Navigator and earns ANRF a spot on their “ 10 Charities Worth Watching ” ...
(Date:6/23/2017)... ... June 23, 2017 , ... Military Connection friend ... entry to the JFK Virgin Atlantic lounge. , Bensko is no stranger to ... years ago, Bensko dedicated her life to supporting our wounded veterans. A world-class photographer, ...
(Date:6/23/2017)... ... June 23, 2017 , ... Georgia ... Sept. 18 to 20. , The two-day conference is focused on advancing scientific ... of improving patients’ lives and eliminating racial breast cancer-related disparities. The conference theme ...
Breaking Medicine News(10 mins):
(Date:6/8/2017)... 8, 2017  StatLab Medical Products ("StatLab" ... manufacturer of diagnostic supplies for the anatomic ... & Company LP ("Cressey & Company"), a ... growth-focused investment in the Company. Cressey & ... from selling shareholder, Prairie Capital, L.P., with ...
(Date:6/7/2017)... 6, 2017  Diplomat Specialty Infusion Group, a brand of Diplomat ... its Iowa location. The ... now features an ISO 7 cleanroom—the standard needed to compound intravenous ... low level of pollutants. "Our ... and better serve our Iowa patients," said ...
(Date:6/3/2017)... June 3, 2017  Eli Lilly and Company ... results from the Phase 3 MONARCH 2 study ... 6 inhibitor, in combination with fulvestrant, significantly improved ... alone in women with hormone-receptor-positive (HR+), human epidermal ... who have relapsed or progressed after endocrine therapy ...
Breaking Medicine Technology: